Newstral
CELG
- What’s Driving Growth For Bristol Myers Squibb Stock?Forbes
- Don’t expect Hochul’s new ethics panel to be better than the old oneNew York Post
- BCelgene Stock Has Soared. One Analyst Says It’s Too Expensive Now.barrons.com
- BBristol-Myers Stock Is Falling Even Though Earnings Beat Expectationsbarrons.com
- MCelgene tops earnings estimates in latest quartermarketwatch.com
- BAcceleron Gives Up on Rare Genetic Disease. Analysts Are Still Bullish on the Stock.barrons.com
- BBristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Saysbarrons.com
- BThe 3 Best Health Care Stocks So Far This Yearbarrons.com
- BAlexion Stock Is Slipping Because an Amgen Bid Looks Less Likelybarrons.com
- BAmgen Stock’s Recent Rally Will Continue. Here’s Why.barrons.com
- BDrug-Trial Data Hurts Bristol Myers, but Earnings Could Triumphbarrons.com
- BBristol-Myers Squibb Falls After Results of Cancer Treatment Study Disappointbarrons.com
- BBristol-Myers Stock Is 'Too Cheap to Ignore'barrons.com
- BRaytheon Stock Is a Winner With or Without United Technologiesbarrons.com
- BDow Goes Nowhere With Trade Talks Loomingbarrons.com
- BSpotify Stock Slumps, Deere Jumps, and the Dow Looks Ready to Risebarrons.com
- MCelgene's stock surges, after Starboard withdraws proxy fight of Bristol-Myers buyout dealmarketwatch.com
- MBristol-Myers to acquire Celgene in cash-and-stock deal with equity value of about $74 billionmarketwatch.com
- MCelgene stock rises after Q3 profit, revenue beatsmarketwatch.com
- MCelgene shares lift on Q2 profit, revenue beats and upbeat 2018 guidancemarketwatch.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.